{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:10:44Z","timestamp":1784563844045,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cmet.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T10:47:18Z","timestamp":1748947638000},"page":"1257-1259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction"],"prefix":"10.1016","volume":"37","author":[{"given":"Subodh","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2186-3166","authenticated-orcid":false,"given":"David A.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2025.05.001_bib1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2025.05.001_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cmet.2025.05.001_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cmet.2025.05.001_bib4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without type 2 diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2025.05.001_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2025.05.001_bib7","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cmet.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cmet.2025.05.001_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacbts.2018.10.005","article-title":"Circulating pro-vascular progenitor cell depletion during type 2 diabetes: translational insights into the prevention of ischemic complications in diabetes","volume":"4","author":"Terenzi","year":"2019","journal-title":"JACC. Basic Transl. Sci."},{"key":"10.1016\/j.cmet.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus","volume":"30","author":"Hess","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2025.05.001_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/eurheartj\/ehab758","article-title":"Vascular repair and regeneration in cardiometabolic diseases","volume":"43","author":"Hess","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cmet.2025.05.001_bib12","doi-asserted-by":"crossref","first-page":"H370","DOI":"10.1152\/ajpheart.00257.2024","article-title":"GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes","volume":"327","author":"Park","year":"2024","journal-title":"Am. J. Physiol. Heart Circ. Physiol."}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413125002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413125002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T23:27:35Z","timestamp":1769038055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413125002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1550413125002578"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2025.05.001","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}